Trial Profile
Randomized Phase III Study of Fulvestrant as Maintenance Therapy After First-line Chemotherapy in HER2 Negative Postmenopausal Metastatic Breast Cancer Patients
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Fulvestrant (Primary)
- Indications Advanced breast cancer; HER2 negative breast cancer
- Focus Registrational; Therapeutic Use
- Acronyms FUMANCE
- 18 Dec 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.
- 12 Mar 2015 New trial record